

## Special Issue

# Gynecological Oncology: Personalized Diagnosis and Therapy

### Message from the Guest Editors

The treatment of gynaecological cancers has, in recent years, seen a transformation away from universal radical extirpative surgery, non-conformal radiotherapy techniques, and a default reliance on platinum-based chemotherapy agents to a wide range of precision medical and surgical interventions, individually targeting both the patient and their cancer. From vaccination and screening for cervical dysplasia and cancer through HPV DNA and RNA techniques to informing drug therapies and prophylactic surgery in endometrial cancer and ovarian cancer, genomic medicine is driving the personalisation of targeted cancer prevention and treatments. This Special Issue welcomes submissions that contain original research in the translational and clinical domains or review articles that demonstrate innovation towards the personalisation of gynaecological cancer detection, prevention, and treatment across surgical, radiation, and medical oncology fields and palliative medicine.

---

### Guest Editors

Dr. Stuart Rundle

Department of Gynaecological Oncology, Queen Elizabeth Hospital,  
Gateshead NE9 6SX, UK

Dr. Ali Kucukmetin

Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital,  
Gateshead NE9 6SX, UK

---

### Deadline for manuscript submissions

31 December 2024



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/204707](https://mdpi.com/si/204707)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://www.mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).